The fairy tale had a good run. For years, Novo Nordisk was the undisputed king of the weight-loss boom, its GLP-1 blockbusters Wegovy and Ozempic commanding premium prices and seemingly limitless demand. But the market narrative has shifted from scarcity to scale, and the Danish pharma giant now finds itself navigating a far less forgiving landscape — one defined by price wars, manufacturing muscle, and a pipeline that has suddenly started showing human fallibility.
The most recent blow landed on Friday, when the company’s Phase 3 ZEUS trial for Ziltivekimab missed its primary endpoint. The drug failed to meaningfully reduce the risk of major cardiovascular events, with a hazard ratio of 0.99 — effectively no benefit over placebo. While Novo Nordisk insisted its 2026 operating profit guidance remains intact, the failed study will trigger a non-cash impairment charge in the third quarter. More importantly, it punctures the so-called “inflammation hypothesis” that many had hoped would become a second growth pillar beyond obesity.
The market has already absorbed much of this disappointment. Shares now trade at €40.91, giving the company a market capitalization of €181.32 billion. That’s roughly 25 percent below the 52-week high of €54.86 touched in January, though still a far cry from the March low of €30.25, from which the stock has recovered by more than a third.
A Structural Shift, Not Just a Bad Week
Friday’s 8.48 percent drop was the sharpest single-day move in recent memory, but the correction that has unfolded over the past seven months tells a deeper story. Novo Nordisk is transitioning from an era of scarcity — when demand for Wegovy and Ozempic vastly outstripped supply — into a phase of industrial-scale mass production. The company has accelerated this shift itself: steep list-price reductions for semaglutide products in the US take effect in 2027, and new subscription pricing models are already being rolled out.
The competitive pressure is relentless. Eli Lilly’s oral candidate Foundayo is muscling into the market, while cheaper compounded copies from US pharmacies are squeezing pricing power from below. Being the sole provider of a miracle drug was a uniquely profitable position; being one of several players in a crowded field is a very different business, with very different margins.
That said, Novo Nordisk still holds roughly 89 percent of the US oral GLP-1 market volume since launching its oral Wegovy pill in January. And while Eli Lilly published encouraging Phase 3 data for Retatrutide on July 23, the oral segment remains Novo’s to lose — for now.
Options Market Braces for a Bigger Swing
All eyes are now on Wednesday, August 5, when Novo Nordisk releases its first-half results. According to Saxo Bank’s calculations, the options market is pricing in an expected move of around eight percent for the US-listed shares — implying a potential trading range of roughly $44.90 to $52.60 around the earnings date. That estimate includes several days of drift beyond the actual trading day, but it still signals an unusually high level of uncertainty.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Historical precedent suggests a more muted reaction: after the last two quarterly reports, the stock fell 6.7 percent and 5.4 percent respectively on the following trading day, per Bloomberg data cited by Saxo. The options market is therefore anticipating a more violent response than investors have typically seen.
Part of that nervousness stems from the fact that expectations have already been reset. Analyst consensus for quarterly earnings per share has been cut by roughly 24 percent over the past year, to around 5.02 Danish kroner. That lower bar makes a positive surprise easier to achieve — but it also reflects genuine doubts about the company’s trajectory.
The analyst community is visibly split. Among 26 analysts covering the Copenhagen-listed B-shares, the consensus rating is “Hold,” with an average price target of 317.20 Danish kroner. The range of individual targets is striking: from 200 to 453 kroner, a spread that underscores deep disagreement about the outcome of the obesity race against Eli Lilly. Across the Atlantic, a broader panel of 37 analysts is more optimistic, with a 68 percent buy rating and an average 12-month target of $51.19.
What Wednesday Will Actually Tell Us
The technical picture offers little clarity. The 200-day moving average sits at €40.34, and the stock is trading barely one percent above it — a level that has served as psychological support since Friday’s slide. The RSI at 41.9 points to neutral-to-slightly-cooled sentiment, with the market waiting for direction rather than committing to a thesis.
Given the lowered earnings bar and the widely anticipated guidance raise — which many believe is already priced in — the market’s reaction on Wednesday may hinge less on the headline numbers and more on management’s commentary. Investors will be listening closely for signals on US pricing trends and the pace of the international rollout of the oral Wegovy pill. The key question: can Novo Nordisk deliver volume growth while prices fall?
The high implied volatility in the options market reflects how binary this event feels to investors. After the ZEUS setback, sentiment was already fragile. Wednesday becomes a test of whether the oral Wegovy growth story can offset intensifying competitive and pricing pressure — and whether the company can prove it is as strong on the factory floor as it once was in the laboratory.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 3 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 3.
Novo Nordisk: Buy or sell? Read more here...
